Microbiome therapeutics go small molecule

Small-molecule drugs and biologics that alter the microbiome or its interaction with host tissues are poised to change the face of microbiome therapeutics.

Search for this author in:

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Reviews Drug Discovery 18, 569-572 (2019)

Updates & Corrections

  • Correction 12 July 2019: The name of the company Kaleido Biosciences and the status of drug candidates it is developing have been corrected in Table 1, and the indication for SYN-010 has been corrected to irritable bowel syndrome with constipation. It has also been clarified that Zehna Therapeutics and Emily Balskus at Harvard University are both separately developing CutC inhibitors.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.